Passage of Magnetic Tat-Conjugated Fe3O4@SiO2 Nanoparticles Across In Vitro Blood-Brain Barrier

Abstract

Delivery of diagnostic or therapeutic agents across the blood-brain barrier (BBB) remains a major challenge of brain disease treatment. Magnetic nanoparticles are actively being developed as drug carriers due to magnetic targeting and subsequently reduced off-target effects. In this paper, we developed a magnetic SiO2@Fe3O4 nanoparticle-based carrier bound to cell-penetrating peptide Tat (SiO2@Fe3O4 -Tat) and studied its fates in accessing BBB. SiO2@Fe3O4-Tat nanoparticles (NPs) exhibited suitable magnetism and good biocompatibility. NPs adding to the apical chamber of in vitro BBB model were found in the U251 glioma cells co-cultured at the bottom of the Transwell, indicating that particles passed through the barrier and taken up by glioma cells. Moreover, the synergistic effects of Tat and magnetic field could promote the efficient cellular internalization and the permeability across the barrier. Besides, functionalization with Tat peptide allowed particles to locate into the nucleus of U251 cells than the non-conjugated NPs. These results suggest that SiO2@Fe3O4-Tat NPs could penetrate the BBB through the transcytosis of brain endothelial cells and magnetically mediated dragging. Therefore, SiO2@Fe3O4-Tat NPs could be exploited as a potential drug delivery system for chemotherapy and gene therapy of brain disease.

Ions-modified nanoparticles affect functional remineralization and energy dissipation through the resin-dentin interface

“…Even more, there exist contradictory results that arise from poor characterization of the NPsloaded biomaterials and their interaction with the target site (Zhao et al, 2016). Active research in this area is helping to build a more solid base in understanding of NPs-tissue interaction.…”

A journey from the endothelium to the tumor tissue: distinct behavior between PEO-PCL micelles and polymersomes nanocarriers

“…( 2008 ) observed translocation of solid lipid nanoparticles through endothelial cells from bovine aortas. Zhao and Lin worked on endothelial layers from blood-brain barrier, for Zhao, there was a possible translocation of the nanoparticles, or for Lin, at least of the nanocarriers charge (Lin et al., 2016 ; Zhao et al., 2016 ). The increase in DiO’s passage induced by a cytokine or cancer cells was more expected.…”

“…For the model of translocation across endothelium, an adaptation of transwell assays (on Boyden chambers) was used. Well-documented for chemotaxis, transwell assays only start to be used to study the passage of nanomaterials across biological barriers such as mucus, aortic, brain, and intestinal barriers (Broughton-Head et al., 2007 ; Jayagopal et al., 2008 ; Cohen et al., 2014 ; Shah et al., 2015 ; Kasper et al., 2016 ; Lin et al., 2016 ; Peuschel et al., 2016 ; Zhao et al., 2016 ; Boya et al., 2017 ; Hsiao et al., 2017 ). So far, this promising and flexible technique had not been used with polymeric nanocarriers or to mimic the endothelium.…”

Targeting with nanoparticles for the therapeutic treatment of brain diseases

“…Cell penetrating peptide TAT or positively charged albumin proteins were often used to coat NPs to enable electrostatic attachment to BBB and penetration. 10,11 Another family of cell penetrating peptide (SynB peptides RGGRLSYSRRRFSTSTGR, Penetratin, Mastoparan) was also reported to increase the drug permeability in a co-cultured BBB model, and to double the drug transport in vivo. 12 However, the stability of cell penetrating peptides in the in vivo conditions is reduced significantly with time that eventually reduces the activity and practical applications.…”